Total management of thalassaemia major.
作者信息
Modell B
出版信息
Arch Dis Child. 1977 Jun;52(6):489-500. doi: 10.1136/adc.52.6.489.
Abstract
摘要
相似文献
1
Total management of thalassaemia major.重型地中海贫血的全面管理。
Arch Dis Child. 1977 Jun;52(6):489-500. doi: 10.1136/adc.52.6.489.
2
Clinical management of beta-thalassemia.β地中海贫血的临床管理
Tex Rep Biol Med. 1980;40:355-64.
3
Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major.
Ann N Y Acad Sci. 1974;232(0):221-5. doi: 10.1111/j.1749-6632.1974.tb20588.x.
4
Chelation therapy, transfusion requirement, and iron balance in young thalassemic patients.年轻地中海贫血患者的螯合疗法、输血需求及铁平衡
Ann N Y Acad Sci. 1980;344:409-17. doi: 10.1111/j.1749-6632.1980.tb33680.x.
5
[Our experience with "supertransfusive" treatment of homozygous beta-thalassemia].
Pediatria (Napoli). 1983 Jan-Mar;91(1):27-30.
6
The management of the improved prognosis in thalassemia major.重型地中海贫血预后改善的管理。
Birth Defects Orig Artic Ser. 1982;18(7):329-37.
7
Editorial: Thalassemia major: a problem of iron overload.
Ann Intern Med. 1974 Aug;81(2):262-3. doi: 10.7326/0003-4819-81-2-262.
8
Current concepts in the management of thalassemia.地中海贫血管理的当前概念。
Indian J Pediatr. 1987 May-Jun;54(3):379-89. doi: 10.1007/BF02748923.
9
Management of thalassaemia major.
Br Med Bull. 1976 Sep;32(3):270-6. doi: 10.1093/oxfordjournals.bmb.a071374.
10
Management of thalassaemia major.重型地中海贫血的管理
Arch Dis Child. 1983 Dec;58(12):1026-30. doi: 10.1136/adc.58.12.1026.
引用本文的文献
1
Complications of patients with thalassemia major and intermedia in a selected Iranian population.特定伊朗人群中重型和中间型地中海贫血患者的并发症
Caspian J Intern Med. 2022 Fall;13(4):765-771. doi: 10.22088/cjim.13.4.756.
2
Achievement of Pre- and Post-Transfusion Hemoglobin Levels in Adult Transfusion-Dependent Beta Thalassemia: Associated Factors and Relationship to Reduction of Spleen Enlargement.成人依赖输血的β地中海贫血患者输血前后血红蛋白水平的达成情况：相关因素及其与脾脏肿大缩小的关系
Int J Gen Med. 2021 Nov 1;14:7515-7521. doi: 10.2147/IJGM.S338114. eCollection 2021.
3
The transfusion management of beta thalassemia in the United States.美国β地中海贫血的输血管理
Transfusion. 2021 Oct;61(10):3027-3039. doi: 10.1111/trf.16640. Epub 2021 Aug 28.
4
Splenectomy for people with thalassaemia major or intermedia.为重型或中间型地中海贫血患者进行脾切除术。
Cochrane Database Syst Rev. 2019 Sep 17;9(9):CD010517. doi: 10.1002/14651858.CD010517.pub3.
5
Clinical Manifestations of β-Thalassemia Major in Two Different Altitudes; Bushehr and Shahrekord.β-地中海贫血重型在两个不同海拔地区（布什尔和沙赫鲁德）的临床表现
Int J Hematol Oncol Stem Cell Res. 2016 Apr 1;10(2):92-8.
6
Influence of splenectomy on immunoglobulins and complement components in major thalassemia.脾切除术对重型地中海贫血患者免疫球蛋白和补体成分的影响。
Caspian J Intern Med. 2015 Winter;6(1):30-3.
7
Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines.地中海贫血的生长与内分泌紊乱：地中海贫血内分泌并发症国际网络（I-CET）立场声明及指南
Indian J Endocrinol Metab. 2013 Jan;17(1):8-18. doi: 10.4103/2230-8210.107808.
8
Iron chelation therapy in thalassemia syndromes.地中海贫血综合征中的铁螯合疗法。
Mediterr J Hematol Infect Dis. 2009 Dec 29;1(1):e2009034. doi: 10.4084/MJHID.2009.034.
9
Congenital dyserythropoietic anaemia type II (HEMPAS): a family study.II型先天性红细胞生成异常性贫血（HEMPAS）：一项家族研究。
J Clin Pathol. 1980 Dec;33(12):1197-201. doi: 10.1136/jcp.33.12.1197.
10
Successful pregnancy in transfusion-dependent thalassaemia.依赖输血的地中海贫血患者成功妊娠。
Arch Dis Child. 1980 Jul;55(7):572-4. doi: 10.1136/adc.55.7.572.
本文引用的文献
1
POSTSPLENECTOMY INFECTION IN COOLEY'S ANEMIA.库利贫血患者脾切除术后感染
Ann N Y Acad Sci. 1964 Oct 7;119:748-57. doi: 10.1111/j.1749-6632.1965.tb54076.x.
2
TRANSFUSION THERAPY IN COOLEY'S ANEMIA: GROWTH AND HEALTH AS RELATED TO LONG-RANGE HEMOGLOBIN LEVELS. A PROGRESS REPORT.库利贫血的输血治疗：与长期血红蛋白水平相关的生长和健康。一份进展报告。
Ann N Y Acad Sci. 1964 Oct 7;119:736-47. doi: 10.1111/j.1749-6632.1965.tb54075.x.
3
COMPARISON OF SIXTY-SIX PATIENTS WITH THALASSEMIA MAJOR AND THIRTEEN PATIENTS WITH THALASSEMIA INTERMEDIA: INCLUDING EVALUATIONS OF GROWTH, DEVELOPMENT, MATURATION AND PROGNOSIS.66例重型地中海贫血患者与13例中间型地中海贫血患者的比较：包括生长、发育、成熟度及预后评估。
Ann N Y Acad Sci. 1964 Oct 7;119:727-35. doi: 10.1111/j.1749-6632.1965.tb54074.x.
4
Iron excretion in thalassaemia major after administration of chelating agents.重型地中海贫血患者在使用螯合剂后的铁排泄情况。
Br Med J. 1962 Dec 15;2(5319):1577-80. doi: 10.1136/bmj.2.5319.1577.
5
6
A genetic study of Mediterranean anaemia in Cyprus.塞浦路斯地中海贫血的基因研究。
Am J Hum Genet. 1951 Mar;3(1):47-64.
7
Longitudinal growth in thalassemia major. Relationship to hemoglobin level.重型地中海贫血的纵向生长。与血红蛋白水平的关系。
Am J Dis Child. 1966 Nov;112(5):396-401. doi: 10.1001/archpedi.1966.02090140068003.
8
Differential ferrioxamine test in idiopathic haemochromatosis and transfusional haemosiderosis.特发性血色素沉着症和输血性血色素沉着症的去铁胺鉴别试验
J Clin Pathol. 1966 Mar;19(2):159-64. doi: 10.1136/jcp.19.2.159.
9
Clinical and laboratory studies on the action of desferrioxamine.
Br J Haematol. 1969 Sep;17(3):257-63. doi: 10.1111/j.1365-2141.1969.tb01371.x.
10
The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion.
Br J Haematol. 1969 Dec;17(6):563-8. doi: 10.1111/j.1365-2141.1969.tb01407.x.
Zotero 插件